Navigation Links
Genzyme Reports Strong First-Quarter Growth
Date:4/23/2008

zyme produced at the 2000L capacity and the timing thereof; its plans to seek regulatory approvals of existing products for use in new indications, including Renvela for CKD, the timetables therefore and the impact of such approvals on the company; its plans and estimated timetables for new and next- generation product filings, regulatory actions and launches, including for Mozobil, Clolar, alemtuzumab-MS, mipomersen, Genz-112638 and Synvisc-ONE and the assessment of the market potential of such products; its projected Myozyme revenues for 2008; and its anticipated growth drivers for certain products and businesses, including Genetics and Thymoglobulin. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those forecasted. These risks and uncertainties include, among others: Genzyme's ability to successfully complete preclinical and clinical development of its products and product candidates, including Mozobil, Clolar, alemtuzumab-MS, mipomersen, and Genz-112638; Genzyme's ability to expand the use of current and next-generation products in existing and new indications, including Renvela and Synvisc-ONE; Genzyme's ability to obtain and maintain regulatory approvals for products and manufacturing facilities, including Myozyme produced at the 2000L scale in the US and at the 4000L scale in Europe and the timing of receipt of such approvals; Genzyme's ability to manufacture its products, including Thymoglobulin and its LSD therapies in a timely and cost effective manner and in sufficient quantities to meet demand; and the risks and uncertainties described in Genzyme's SEC reports filed under the Securities Exchange Act of 1934, including the factors discussed under the caption "Risk Factors" in Genzyme's 2007 Annual Report on Form 10-K. Genzyme cautions investors not to place substantial reliance on the forward-looking statements contained in this press release. These statements speak only as of today's date
'/>"/>
SOURCE Genzyme Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related biology technology :

1. Genzyme to Build New R&D Center in Beijing
2. Genzyme Provides Update on Myozyme(R) Manufacturing
3. Genzyme Withdraws Bioenvisions European Filing of Evoltra(R) in Elderly AML Patients
4. Genzyme Launches Renvela(R) in the U.S. for Dialysis Patients
5. Genzyme and Isis Announce Hart-Scott-Rodino Approval of Collaboration
6. Genzyme and Isis Announce Strategic Alliance Including Exclusive Worldwide License of Mipomersen
7. BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture
8. Genzyme Receives European CE Mark for Single-Treatment Synvisc-One(TM)
9. Genzyme Announces FDA Approval of Thyrogen(R) for Use in Thyroid Cancer Ablation
10. Genzyme Study of Myozyme(R) for Late-Onset Pompe Patients Meets Co-Primary Efficacy Endpoints
11. Genzyme and Sunway to Collaborate on Gene Therapy Program in China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... “PharmaSphere: Emerging Biotech Investment Report ... Funding” report provides in-depth analysis of the current ... venture capital segments of the financial industry, bearing ... significant impact on the future of emerging biotechnology ... report identifies regions of the world that are ...
(Date:7/29/2014)... Cat: Can a particle be separated from its properties? ... , published the results of the first Cheshire Cat ... by Chapman University in Orange, CA, and Vienna University ... cat without a grin," thought Alice in Wonderland, "but ... thing I ever saw in my life!" Alice,s surprise ...
(Date:7/29/2014)... 29, 2014 Second generation biofuels are a ... fossil fuels. However, as natural gas is very cheap, this ... are not as valuable as they could be in comparison ... financing projects, has made it difficult for renewable energy developers ... off the ground. For these reasons, certain companies have shifted ...
(Date:7/29/2014)... COLORADO SPRINGS, Colo. , July 29, 2014 ... Company specializing in cannabis formulation-based drug development and ... New York Times for taking a strong position ... in its Sunday, July 27, 2014 publication.  The ... upcoming editorials and articles this week exploring the ...
Breaking Biology Technology:Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 2Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 3Strategic Trends of Biotech Investment Industry (Private Equity and Venture Capital Funding) in New Report Available at MarketOptimizer.org 4The quantum Cheshire cat: Scientists separate a particle from its properties 2The quantum Cheshire cat: Scientists separate a particle from its properties 3The quantum Cheshire cat: Scientists separate a particle from its properties 4Renewable Waste Intelligence: Could Renewable Chemicals Be the Future for the Renewable Energy Industry? 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 2Cannabis Science, Inc. (CBIS) Applauds New York Times Editorial Board Stance on 'Repealing Prohibition, Again'; NYT Editorial Is Bell Weather of Change 3
... research team co-led by scientists from the J. Craig Venter ... of Maryland School of Medicine, today published the sequence and ... in Nature Biotechnology . Agnes P. Chan, Ph.D., JCVI, ... paper describing the 4.5X coverage of this important oilseed crop. ...
... In Vitro Toxicology Services -- MACCLESFIELD, England, August 20, 2010 ... ... var shortURL ... longUrl, so we need to grab the first one. for (var r in data.results) { first_result = ...
... SLN), a leading international RNAi therapeutics company, is pleased ... has announced the grant of an option to Novartis ... commercialise QPI-1002, a p53 temporary inhibitor siRNA drug which ... conducting a Phase II clinical trial of QPI-1002 for ...
Cached Biology Technology:Castor Bean Genome Published by Research Team Including Scientists from the Venter Institute 2Castor Bean Genome Published by Research Team Including Scientists from the Venter Institute 3Cyprotex Adds In Vitro Toxicology Services 2Cyprotex Adds In Vitro Toxicology Services 3Cyprotex Adds In Vitro Toxicology Services 4Cyprotex Adds In Vitro Toxicology Services 5Cyprotex Adds In Vitro Toxicology Services 6Silence Therapeutics' Partner Quark Signs Exclusive Option Agreement With Novartis for Development and Commercialisation of QPI-1002 2
(Date:7/29/2014)... brings together two of the major disciplines behind Jurassic ... fossils through stunning photographs and unique illustrations. , Fossil ... details the incredible preservation and diversity of fossilised insects ... these remarkable fossils can tell us about the ancient ... planet. Like the mosquito in Jurassic Park, many of ...
(Date:7/29/2014)... study from UC San Francisco is the first to ... overtime and accelerate cellular aging, these negative effects may ... sleeping well. , "The study participants who exercised, ... than the ones who didn,t maintain healthy lifestyles, even ... author Eli Puterman, PhD, assistant professor in the department ...
(Date:7/28/2014)... Amundsen reached the South Pole in 1911, but new ... any human. , Using data from 16 ice cores ... including the South Pole, a group led by Joe ... Nevada, created the most accurate and precise reconstruction to ... new record, described in an article published today in ...
Breaking Biology News(10 mins):Unique images bring fossil insects back to life 2Healthy lifestyle may buffer against stress-related cell aging, study says 2Lead pollution beat explorers to South Pole, persists today 2Lead pollution beat explorers to South Pole, persists today 3
... time when research funding is hard to come by, a ... landed almost $5.5 million in National Institutes of Health highly ... $3.6 million over five years is aimed at determining whether ... of hemophilia A more effective. The second grant worth $2 ...
... will be floating high above the Gulf of Mexico ... DNA analysis instrument developed at Tech that could benefit ... of mechanical engineering, and Collin Tranter, a graduate student ... instrument could be used to monitor the health of ...
... to react when their animals start behaving abnormally. The ... the symptoms are so variable. In some cases the ... which is generally considered to be how most cats spend ... is followed by twitching of facial muscles, chewing and swallowing ...
Cached Biology News:Hemophilia research gets NIH boost to a tune of $5.5 million 2Hemophilia research gets NIH boost to a tune of $5.5 million 3Louisiana Tech University researchers, NASA partner to conduct zero-gravity experiments 2Seizing the opportunity: treating epilepsy in cats 2
Request Info...
... Universal Amplicon Detection Assay (ADA) ... the qualitative detection and quantitation ... in vitro nucleic acid amplification. ... to be used in diagnostic ...
{3,8-diamino-5-[3-(diethylmethylammonio)propyl]-6-phenylphenanthridinium diiodide}. ,250 ug/ml Propidium Iodide (PI) in PBS....
... ready-to-use reagents for the isolation of genomic ... for the isolation of genomic DNA from ... for the isolation of genomic DNA from ... can be used for restriction endonuclease digestion ...
Biology Products: